Antifungal drug development: challenges, unmet clinical needs, and new approaches

Area of Science:

• Mycology
• Infectious Diseases
• Pharmacology

Background:

• Invasive fungal infections pose a significant threat, leading to high morbidity and mortality rates, especially in immunocompromised patients.
• Current therapeutic options for invasive fungal infections are severely limited compared to antibacterial treatments.
• Only three drug classes are clinically available, with no new class developed in three decades.

Purpose of the Study:

• To summarize the unmet clinical needs in current antifungal therapy.
• To discuss the challenges associated with antifungal drug discovery and development.
• To review recent advancements addressing these challenges.

Main Methods:

• Literature review of current antifungal therapies.
• Analysis of challenges in antifungal drug discovery pipelines.
• Summary of recent developments in antifungal research.

Main Results:

• Significant unmet needs exist in treating invasive fungal infections.
• Antifungal drug discovery faces numerous hurdles, including toxicity and resistance.
• Recent research shows promise in developing novel antifungal agents and strategies.

Conclusions:

• There is an urgent need for novel antifungal drugs to combat rising resistance and limited treatment options.
• Overcoming challenges in drug discovery is crucial for advancing antifungal therapy.
• Continued research and development are essential to address the global burden of invasive fungal infections.